# Aperiam Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aperiam-bio

- Industry: Business Support Services
- Headquarters: New York, US
- Website: www.aperiambio.com
- Total disclosed funding: $4M
- Latest round: Seed (Sep 18, 2023)
- Investors on record: 4

## About

Based in New York, US, and founded by Austin Cole (CEO) in 2021, Aperiam Bio, Inc. operates as a protein engineering company. In November 2023, the firm raised USD 9 million in seed funding led by investor OMX Ventures, with participation from other investors Axial VC, KDT Ventures, and Civilization Ventures.

The company engineers hyperfolding variants of protein, with improvements in expression, solubility, and specific activity. Aperiam's high-performing products span technical reagents, cosmetics, and pulmonary biologics. By identifying stabilizing mutations and creating shelf-stable enzymes, the company addresses challenges in manufacturing, consumer cosmetics, and therapeutic applications. 

The company plans to utilize the November 2023 funding to improve its product development capacity and establish strong partnerships with companies.

## Funding rounds

- Seed, Sep 18, 2023, $4M — KdT Ventures, Civilization Ventures, OMX Ventures, Axial VC

## Investors

- KdT Ventures (https://capitalatlas.ai/funds/kdt-ventures) — Seed
- Civilization Ventures (https://capitalatlas.ai/funds/civilization-ventures) — Seed
- OMX Ventures (https://capitalatlas.ai/funds/omx-ventures) — Seed
- Axial VC (https://capitalatlas.ai/funds/axial-vc) — Seed